Moorcrofts LLP has advised the shareholders of Curo Consulting, a global pharma market access consultancy, on the company’s sale to Envision Pharma Group.

A longstanding client of Moorcrofts, Marlow-based Curo specialises in enabling biopharma companies to communicate with payers, policy makers, and providers ‘in their language’. Curo won the Queen’s Award for Enterprise – International Trade in 2015, the UK’s highest accolade for business success.

Operating globally, Envision is a global, innovative technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies.

The acquisition was supported by Envision’s private equity partners – Ardian, the independent private investment company, and GHO Capital, the specialist European investor in healthcare.

Curo CEO Christopher O’Neill said: “We are absolutely delighted to become part of Envision, as we have found a partner with the same commitment to combining services with supporting technology.”

Moorcrofts’ corporate partner, Adrian Phillips, led the deal, with support from Peter Woolley and Nupur Shah. Employment support was provided by Matt Jenkin and Sally Nesbitt.

Curo managing director Jonathan Mowll commented: “We really do appreciate Moorcrofts’ hard work and particularly their experience in this process. Moorcrofts displayed impressive energy to drive things on to the next step. It has been rewarding working with the Moorcrofts team, we always felt assured that they had everything under control, and that is what really counts!”

Adrian Phillips said: “We were delighted to act on behalf of the Curo shareholders on this transaction. We wish them every success in their new roles with Envision, and we hope Curo will achieve its strategic ambitions as part of the Envision Pharma Group.”

James Cowper LLP provided corporate finance and tax advice for the Curo shareholders.